6mei - Revision history

OCA at 08:24, 6 November 2019

OCA — Wed, 06 Nov 2019 08:24:38 GMT

←Older revision		Revision as of 08:24, 6 November 2019
Line 1:		Line 1:

-	==~~Broadly~~ neutralizing ~~antibodies against HCV use a CDRH3 disulfide motif to recognize an E2~~ glycoprotein ~~site that can be targeted for vaccine design~~==	+	==Crystal structure of broadly neutralizing antibody HEPC3 in complex with Hepatitis C virus envelope glycoprotein E2 ectodomain==
-	<StructureSection load='6mei' size='340' side='right' caption='[[6mei]], [[Resolution\|resolution]] 2.90Å' scene=''>	+	<StructureSection load='6mei' size='340' side='right'caption='[[6mei]], [[Resolution\|resolution]] 2.90Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[6mei]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/9hepc 9hepc] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEI FirstGlance]. <br>		<table><tr><td colspan='2'>[[6mei]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/9hepc 9hepc] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEI FirstGlance]. <br>
Line 16:		Line 16:
	</div>		</div>
	<div class="pdbe-citations 6mei" style="background-color:#fffaf0;"></div>		<div class="pdbe-citations 6mei" style="background-color:#fffaf0;"></div>
		+
		+	==See Also==
		+	*[[Antibody 3D structures\|Antibody 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
Line 21:		Line 24:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
		+	[[Category: Large Structures]]
	[[Category: Bjorkman, P J]]		[[Category: Bjorkman, P J]]
	[[Category: Flyak, A I]]		[[Category: Flyak, A I]]

OCA at 21:10, 2 December 2018

OCA — Sun, 02 Dec 2018 21:10:05 GMT

←Older revision		Revision as of 21:10, 2 December 2018
Line 1:		Line 1:
-	'''Unreleased structure'''

-	~~The entry~~ 6mei is ~~ON HOLD until Paper~~ Publication	+	==Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design==
		+	<StructureSection load='6mei' size='340' side='right' caption='[[6mei]], [[Resolution\|resolution]] 2.90Å' scene=''>
		+	== Structural highlights ==
		+	<table><tr><td colspan='2'>[[6mei]] is a 3 chain structure with sequence from [http://en.wikipedia.org/wiki/9hepc 9hepc] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6MEI OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6MEI FirstGlance]. <br>
		+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=BMA:BETA-D-MANNOSE'>BMA</scene>, <scene name='pdbligand=BR:BROMIDE+ION'>BR</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene></td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6mei FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6mei OCA], [http://pdbe.org/6mei PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6mei RCSB], [http://www.ebi.ac.uk/pdbsum/6mei PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6mei ProSAT]</span></td></tr>
		+	</table>
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	Hepatitis C virus (HCV) vaccine efforts are hampered by the extensive genetic diversity of HCV envelope glycoproteins E1 and E2. Structures of broadly neutralizing antibodies (bNAbs) (e.g., HEPC3, HEPC74) isolated from individuals who spontaneously cleared HCV infection facilitate immunogen design to elicit antibodies against multiple HCV variants. However, challenges in expressing HCV glycoproteins previously limited bNAb-HCV structures to complexes with truncated E2 cores. Here we describe crystal structures of full-length E2 ectodomain complexes with HEPC3 and HEPC74, revealing lock-and-key antibody-antigen interactions, E2 regions (including a target of immunogen design) that were truncated or disordered in E2 cores, and an antibody CDRH3 disulfide motif that exhibits common interactions with a conserved epitope despite different bNAb-E2 binding orientations. The structures display unusual features relevant to common genetic signatures of HCV bNAbs and demonstrate extraordinary plasticity in antibody-antigen interactions. In addition, E2 variants that bind HEPC3/HEPC74-like germline precursors may represent candidate vaccine immunogens.

-	~~Authors:~~ Flyak, ~~A.I.~~, ~~Bjorkman~~, P.J.	+	HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design.,Flyak AI, Ruiz S, Colbert MD, Luong T, Crowe JE Jr, Bailey JR, Bjorkman PJ Cell Host Microbe. 2018 Nov 14;24(5):703-716.e3. doi: 10.1016/j.chom.2018.10.009. PMID:30439340<ref>PMID:30439340</ref>

-	~~Description: Broadly neutralizing antibodies against HCV use~~ a ~~CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design~~	+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
-	[[Category: ~~Unreleased Structures~~]]	+	</div>
-	[[Category: Bjorkman, P.J]]	+	<div class="pdbe-citations 6mei" style="background-color:#fffaf0;"></div>
-	[[Category: Flyak, A.I]]	+	== References ==
		+	<references/>
		+	__TOC__
		+	</StructureSection>
		+	[[Category: Human]]
		+	[[Category: Bjorkman, P J]]
		+	[[Category: Flyak, A I]]
		+	[[Category: Broadly neutralizing antibody]]
		+	[[Category: Hcv glycoprotein]]
		+	[[Category: Immune system]]

OCA at 06:27, 26 September 2018

OCA — Wed, 26 Sep 2018 06:27:46 GMT

←Older revision		Revision as of 06:27, 26 September 2018
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 6mei is ON HOLD	+	The entry 6mei is ON HOLD until Paper Publication

	Authors: Flyak, A.I., Bjorkman, P.J.		Authors: Flyak, A.I., Bjorkman, P.J.

OCA: Protected "6mei" [edit=sysop:move=sysop]

OCA — Wed, 12 Sep 2018 06:18:50 GMT

Protected "6mei" [edit=sysop:move=sysop]

←Older revision

Revision as of 06:18, 12 September 2018

OCA: New page: '''Unreleased structure''' The entry 6mei is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

OCA — Wed, 12 Sep 2018 06:18:49 GMT

New page: '''Unreleased structure''' The entry 6mei is ON HOLD Authors: Flyak, A.I., Bjorkman, P.J. Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recogn...

New page

'''Unreleased structure'''

The entry 6mei is ON HOLD

Authors: Flyak, A.I., Bjorkman, P.J.

Description: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design
[[Category: Unreleased Structures]]
[[Category: Bjorkman, P.J]]
[[Category: Flyak, A.I]]